Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.
Also called NCT03797001
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 102 participants
- Registry
-
NCT03797001
-
- Other papers using this trial's data
- Interleukin-1 Receptor Antagonist Levels in Patients With Heart Failure and Reduced Ejection Fraction Treated With Anakinra
- Resolution of Systemic Inflammation in Patients With Recently Decompensated Heart Failure With Reduced Ejection Fraction With and Without Interleukin-1 Blockade by Anakinra
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03797001. Randomized; quadruple masking; primary purpose treatment. Start 2019-01-04 (actual); primary completion 2024-07-22 (actual). Results posted on 2025-08-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2
- Acronym
- REDHART2
- Condition
- Heart Failure, Systolic
- Condition
- Inflammation
- Intervention (Drug)
- Anakinra
- Intervention (Drug)
- Placebo
- Lead sponsor
- Virginia Commonwealth University
Record details
- Record id
cardio:ct-nct03797001- Content hash
bca32309c3efec49476422627caf9c4e1cbaaad48471566a6d2bb481fca59f35